Premium
Sevelamer in a diabetologist's perspective: a phosphate‐binding resin with glucose‐lowering potential
Author(s) -
Brønden A.,
Hansen M.,
Sonne D. P.,
Rohde U.,
Vilsbøll T.,
Knop F. K.
Publication year - 2015
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12355
Subject(s) - sevelamer , medicine , phosphate binder , phosphate , drug , pharmacology , kidney disease , diabetes mellitus , endocrinology , biochemistry , chemistry , hyperphosphatemia
Sevelamer is a calcium‐free and metal‐free phosphate‐binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid‐lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These ‘novel’ effects are most probably derived from the bile acid‐binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose‐lowering effect of the drug.